How long does Tesamorelin stay in your system?
Tesamorelin has a published half-life of 8 minutes (Egrifta SV), 11 minutes (Egrifta WR). By the standard pharmacology rule of thumb, a drug is about 97% eliminated after roughly five half-lives, which here works out to between 40 and 55 minutes. That is 40 minutes for Egrifta SV and 55 minutes for Egrifta WR.
Source: Egrifta SV label, DailyMed · FDA label · measured: subcutaneous, single dose, healthy subjects · dataset reviewed September 23, 2026
What is the half-life of Tesamorelin?
The current Egrifta SV prescribing information gives tesamorelin a half-life of 8 minutes for Egrifta SV and 11 minutes for Egrifta WR, measured after a single subcutaneous dose in healthy subjects. Tesamorelin is a stabilised analogue of growth hormone-releasing hormone, and it is one of the few compounds in its class with full FDA approval.
A hexenoyl group attached to its N-terminus resists enzymes such as DPP-4 and extends its half-life relative to native GHRH. Even so, tesamorelin remains a minutes-scale molecule. It does not use albumin binding the way CJC-1295 with DAC does, which is why that compound is measured in days instead.
How much Tesamorelin is left after each half-life?
Each half-life removes half of whatever is left, so the percentages are pure arithmetic and the same for any compound; only the clock changes. For Tesamorelin, one half-life is 8 to 11 minutes. The rows below run that forward for a single amount with nothing added.
| Half-lives elapsed | Time elapsed | Remaining | Cleared |
|---|---|---|---|
| 1 | 8 to 11 minutes | 50% | 50% |
| 2 | 16 to 22 minutes | 25% | 75% |
| 3 | 24 to 33 minutes | 12.5% | 87.5% |
| 4 | 32 to 44 minutes | 6.25% | 93.75% |
| 5 | 40 to 55 minutes | 3.13% | 96.88% |
| 6 | 48 to 66 minutes | 1.56% | 98.44% |
| 7 | 56 to 77 minutes | 0.78% | 99.22% |
Why do the numbers differ between sources?
Tesamorelin is the clearest example on this site of a number that changed for real reasons. An earlier Egrifta label reported 26 minutes in healthy subjects and 38 minutes in HIV-infected patients after 14 consecutive days. The current label reports 8 minutes for SV and 11 minutes for WR.
The difference is formulation and repeat dosing, not route. Egrifta has never had an intravenous presentation, so any explanation that attributes the gap to intravenous versus subcutaneous measurement is mistaken. The older 26 and 38 minute figures were genuine label values, for an earlier product and a different measurement context.
What does a half-life not tell you?
Tesamorelin works by prompting the pituitary to release the body's own growth hormone, which then drives IGF-1 production in the liver. The peptide clears within minutes, but the growth hormone pulse it provokes and the IGF-1 that follows run on their own, slower clocks. Tesamorelin's half-life says nothing about how long either stays elevated.
Nor does it describe the reduction in visceral fat that the approval rests on. That effect builds over a course of treatment and reverses after it stops, according to the evidence summarised on the profile, which makes it a question for outcome data rather than a decay curve measured in minutes.
Can you run the numbers yourself?
The estimator applies the same decay arithmetic to any half-life, starting amount and time you enter. It opens with Tesamorelin's published value loaded. Type another figure to see how sensitive the result is to it.
Published value: 8 minutes (Egrifta SV), 11 minutes (Egrifta WR) (Subcutaneous, single dose, healthy subjects) · Egrifta SV label, DailyMed · Compound profile
Show the math
What are the limits of this estimate?
Everything above is a single-compartment approximation: one pool of drug, falling by the same fraction in every interval. Real elimination varies with kidney and liver function, body composition, formulation and route, and a published figure describes only the route and the people it was measured in. Many compounds also show a fast distribution phase before the slower elimination the table describes.
A half-life is not a dosing schedule. Labelled intervals come from clinical trials that measured outcomes and tolerability, and nothing on this page suggests when to take, repeat or stop anything. Whether Tesamorelin is out of your system for drug-testing purposes is a different question again. Tests often look for metabolites rather than the parent compound, and the answer depends on the assay, its sensitivity and the sample type, none of which a plasma half-life captures.
FAQ.
Why are there two half-lives for tesamorelin?
Because there are two current formulations. The Egrifta SV label gives 8 minutes for Egrifta SV and 11 minutes for Egrifta WR, both after a single subcutaneous dose in healthy subjects. Formulation changes how a peptide is released and handled, so each presentation gets its own number.
Is the older 26 minute figure wrong?
No. It was a real value on an earlier Egrifta label, reported for healthy subjects alongside 38 minutes in HIV-infected patients after 14 consecutive days. It reflects an earlier formulation and repeat dosing, not the current products.
Does growth hormone stay elevated after tesamorelin is cleared?
The two curves are separate. Tesamorelin itself leaves plasma within minutes, while the growth hormone it releases and the IGF-1 produced downstream follow their own kinetics. We do not give figures for those curves here because they are not part of the sourced tesamorelin data.
For what the evidence on Tesamorelin actually shows, read the Tesamorelin profile. For approval and regulatory position, see is Tesamorelin legal. The half-life reference lists every sourced value side by side, including the compounds where a number circulates online with no reliable human data behind it.